Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Taxes (2018 - 2025)

Ligand Pharmaceuticals' Change in Taxes history spans 8 years, with the latest figure at $955000.0 for Q4 2025.

  • For Q4 2025, Change in Taxes rose 132.74% year-over-year to $955000.0; the TTM value through Dec 2025 reached -$2.7 million, down 15.45%, while the annual FY2025 figure was -$2.7 million, 15.45% down from the prior year.
  • Change in Taxes for Q4 2025 was $955000.0 at Ligand Pharmaceuticals, up from -$864000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $12.0 million in Q1 2022 and bottomed at -$16.7 million in Q4 2022.
  • The 5-year median for Change in Taxes is -$908500.0 (2024), against an average of -$39950.0.
  • The largest YoY upside for Change in Taxes was 1018.75% in 2022 against a maximum downside of 304.96% in 2022.
  • A 5-year view of Change in Taxes shows it stood at $8.1 million in 2021, then tumbled by 304.96% to -$16.7 million in 2022, then soared by 145.53% to $7.6 million in 2023, then crashed by 138.39% to -$2.9 million in 2024, then surged by 132.74% to $955000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Change in Taxes are $955000.0 (Q4 2025), -$864000.0 (Q3 2025), and -$2.4 million (Q2 2025).